Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a specialty pharmaceutical company focused on developing abuse-deterrent and overdose-prevention drug formulations. The company entered the public markets through a SPAC merger completed in 2021, transitioning from a blank-check vehicle to an operating life-sciences entity listed on Nasdaq. Ensysce filed an 8-K current report with the Securities and Exchange Commission on January 8, 2026, disclosing a material corporate development. The company operates within the specialty pharmaceuticals sector, with its clinical pipeline addressing opioid abuse and addiction. Investors and analysts seeking complete filing histories, SPAC transaction records, and real-time monitoring tools can sign up for full access at SpacDesk.